| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,768 |
10,216 |
$716K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,520 |
7,111 |
$333K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
680 |
657 |
$35K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
975 |
962 |
$35K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
656 |
620 |
$33K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
814 |
804 |
$31K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
191 |
180 |
$18K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
109 |
104 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
946 |
891 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
512 |
495 |
$6K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
253 |
246 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
88 |
87 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
102 |
102 |
$4K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
26 |
26 |
$4K |
| 87081 |
|
816 |
774 |
$3K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
12 |
12 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
12 |
12 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
42 |
39 |
$393.98 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
36 |
26 |
$347.99 |
| 81001 |
|
99 |
95 |
$324.95 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
12 |
12 |
$285.24 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
26 |
24 |
$202.12 |
| 36415 |
Collection of venous blood by venipuncture |
99 |
95 |
$176.09 |
| 71045 |
Radiologic examination, chest; single view |
13 |
12 |
$121.74 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12 |
12 |
$98.92 |